Welcome to our dedicated page for Nuvectis Pharma news (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma stock.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) is a clinical-stage biopharmaceutical company developing precision oncology small molecule therapies, and its news flow reflects the progress of these programs. Company announcements frequently highlight clinical milestones for its lead SRC/YES1 kinase inhibitor NXP900 and its GCN2 activator NXP800, as well as corporate and financial updates.
News items for Nuvectis often cover clinical trial developments, including the completion of the NXP900 Phase 1a dose escalation study in advanced solid tumors, results from a drug-drug interaction study in healthy volunteers, and the initiation of the Phase 1b program. Updates describe the single-agent Phase 1b component in genomically selected advanced cancers and combination studies with EGFR and ALK inhibitors in non-small cell lung cancer, including a study combining NXP900 with osimertinib in EGFR-mutated NSCLC that has developed resistance.
Investors and followers of NVCT can also find scientific conference coverage in the company’s news, such as poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. These items summarize emerging safety, pharmacokinetic, pharmacodynamic and preclinical data that inform the biomarker-based strategy for NXP900.
Additional news includes pipeline updates for NXP800, including final Phase 1b data in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer and the company’s decision to explore potential opportunities for NXP800 in other cancer types. Nuvectis also issues financial results and business highlights via quarterly earnings press releases, along with corporate developments such as board appointments and participation in investment conferences. For investors tracking NVCT, this news stream provides ongoing insight into clinical progress, scientific rationale and corporate strategy.
Nuvectis Pharma (NASDAQ: NVCT) has announced the pricing of its public offering of 2,700,000 shares of common stock at $5.00 per share, expecting to raise gross proceeds of $13.5 million. The company has granted the underwriter a 30-day option to purchase up to 405,000 additional shares at the same price.
The offering is expected to close on February 6, 2025, with Lucid Capital Markets acting as the sole book runner. The proceeds will be used to advance development programs of NXP800 and NXP900, hire additional personnel, cover capital expenditures, operating costs as a public company, and other general corporate purposes.
The offering is being made pursuant to Nuvectis's shelf registration statement on Form S-3, which was declared effective by the SEC on March 29, 2023.
Nuvectis Pharma (NVCT) has announced the commencement of an underwritten public offering of its common stock. The clinical-stage biopharmaceutical company, focused on developing precision medicines for oncology, will be the sole provider of all shares in the offering. Lucid Capital Markets is acting as the sole book runner.
The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares. The net proceeds will fund the development of NXP800 and NXP900 programs, personnel hiring, capital expenditures, public company operating costs, and general corporate purposes.
The offering is being made pursuant to a shelf registration statement (File No. 333-270657) declared effective by the SEC on March 29, 2023. The completion, size, and terms of the offering are subject to market conditions.
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium. The company's Chairman and CEO, Ron Bentsur, will deliver a presentation at the event scheduled for December 12, 2024, at 10 am EST.
Nuvectis Pharma reported encouraging interim data from its Phase 1b study of NXP800 in platinum-resistant ARID1a-mutated ovarian cancer patients. The study evaluated three dosing regimens in twelve patients, with one showing unconfirmed partial response and six achieving stable disease with tumor shrinkage. The new intermittent dosing schedule (50 mg/day, 5 days on/2 days off) successfully minimized thrombocytopenia concerns. The company is now enrolling patients for a higher dose intensity cohort at 75 mg/day on an intermittent schedule, with additional clinical data expected in Q2 2025.
Nuvectis Pharma reported Q3 2024 financial results and business updates. Cash position was $17.2M as of September 30, 2024, down from $19.1M in December 2023. Net loss decreased to $4.2M from $5.9M year-over-year. R&D expenses reduced to $2.8M from $4.5M, while G&A expenses decreased to $1.5M from $1.7M. The company expects clinical data update from NXP800 Phase 1b study this month, with the drug receiving Orphan Drug Designation for ARID1a-deficient cancers. NXP900 Phase 1a study completed 4 escalation cohorts with no dose-limiting toxicities.
Nuvectis Pharma (NASDAQ: NVCT) showcased promising results at the AACR-NCI-EORTC Symposium, where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in resistant non-small cell lung cancer (NSCLC) cells. The drug effectively targets SRC/YES1 kinases, addressing resistance mechanisms in cancer treatment.
The company is also anticipating data updates from NXP800's Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer. With a current market valuation of approximately $150 million, Nuvectis is positioning itself alongside industry players like Summit Therapeutics ($15B) and Nuvalent ($6.6B) in the precision oncology space.
Nuvectis Pharma (NASDAQ: NVCT) has announced two upcoming scientific presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain (October 23-25, 2024).
The first presentation by Asier Unciti-Broceta from the University of Edinburgh will showcase NXP900's synergy with ALK inhibitors in ALK resistant cell lines. This poster session is scheduled for October 24th, 2024.
The second presentation by Ben King, also from the University of Edinburgh, will focus on using a multi-omics approach to identify biomarkers responding to NXP900. This poster session will take place on October 25th, 2024.
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in innovative precision medicines for oncology, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is scheduled for October 9, 2024, in New York, NY.
Nuvectis management will take part in a panel discussion focused on 'Innovative Therapies for Solid Tumors'. This panel is set to begin at 12:30 pm ET on the day of the conference.
The company's involvement in this prestigious healthcare conference underscores its commitment to advancing treatments for serious conditions with unmet medical needs in oncology, particularly in the realm of solid tumors.
Nuvectis Pharma's NXP900 is emerging as a promising candidate in the fight against Non-Small Cell Lung Cancer (NSCLC), particularly for patients resistant to EGFR and ALK targeted therapies. Like Summit Therapeutics' Ivonescimab, which recently outperformed Merck's Keytruda in a Phase 3 trial, NXP900 targets treatment resistance but through a different mechanism.
NXP900 inhibits SRC/YES1 kinases, key drivers of cancer survival. Preclinical studies show its potential to reverse resistance to existing therapies and enhance their effectiveness when used in combination. While still in early clinical development, NXP900's targeted approach and potential applications beyond NSCLC make it a noteworthy contender in the evolving landscape of cancer treatment.
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's Chairman and CEO, Ron Bentsur, will be presenting at the event on September 9, 2024, at 12:00 PM ET.
Nuvectis focuses on developing innovative treatments for serious conditions with unmet medical needs in oncology. This presentation at a prominent investment conference provides an opportunity for the company to showcase its progress and potential to investors and industry professionals. Interested parties can access the presentation through a provided link, offering insight into Nuvectis' current projects and future prospects in the oncology field.
FAQ
What is the current stock price of Nuvectis Pharma (NVCT)?
What is the market cap of Nuvectis Pharma (NVCT)?
